Expression of therapeutic levels of factor VIII in hemophilia A mice using a novel adeno/adeno-associated hybrid virus

Summary We have generated an E1a/E1b/E3-deleted adeno/adeno-associated (Ad/AAV) hybrid virus driven by a small nuclear RNA (pHU1-1) promoter for expression of a B domain-deleted (Thr761-Asn1639) factor VIII transgene (FVIIIΔ761-1639). Productive replication of Ad/AAV/FVIIIΔ761-1639 in AAV repexpressing cells resulted in generation of monomeric and dimeric mini-adenoviral (mAd) replicative forms that retained the AAV integration elements (mAd/FVIIIΔ761-1639). In vitro studies using Ad/AAV/FVIIIΔ761-1639 generated ∼2-logs greater FVIII activity than mAd/FVIIIΔ761-1639. To determine its capacity for in vivo excision and/or genomic integration, Ad/AAV/FVIIIΔ761-1639 was injected by tail vein into three groups of hemophilia A mice (2 X 1011 vp [n = 3]; 4 X 1011 vp [n = 3]; 8 X 1011 vp [n = 3]), with clear concentration-dependent increase in FVIII activity (range 160-510 mU/ml; plasma activity 16% – 51% of normal). Peak activity was seen by Day (D) 5, with slow return to baseline by D28 (0.1 – 0.9% activity); in only 3/9 mice was loss of FVIII activity associated with development of anti-FVIII antibodies. Quantitative-PCR using genomic DNA isolated from D28 liver, spleen, heart, lungs, and kidney demonstrated the highest concentration in liver (∼10 genomes/ cell), with little to no organ toxicity at early (D5 or 6) or late (D28) post-infusion time points. There was no evidence for spontaneous transgene excision or genomic integration in vivo as evaluated by quantitative PCR and genomic blotting. These data establish (i) the feasibility and applicability of developing high-titer Ad/AAV hybrid viruses for FVIII delivery using a small cellular promoter, (ii) the potential utility of this virus for generation of “gutted” monomeric and dimeric mAD/FVIII retaining AAV integration elements, and (iii) that the development of strategies for regulated Rep68/78 co-expression may provide a novel approach for excision, integration, and long-term FVIII transgene expression.

[1]  A. Parker,et al.  Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector. , 2003, Blood.

[2]  P. Perrotta,et al.  Transcript profiling of human platelets using microarray and serial analysis of gene expression. , 2003, Blood.

[3]  S. Kochanek,et al.  Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors. , 2003, Blood.

[4]  N. Philpott,et al.  A p5 integration efficiency element mediates Rep-dependent integration into AAVS1 at chromosome 19 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[5]  N. Philpott,et al.  Efficient Integration of Recombinant Adeno-Associated Virus DNA Vectors Requires a p5-rep Sequence in cis , 2002, Journal of Virology.

[6]  D. Kayda,et al.  Sustained human factor VIII expression in hemophilia A mice following systemic delivery of a gutless adenoviral vector. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  Theresa A. Storm,et al.  Extrachromosomal Recombinant Adeno-Associated Virus Vector Genomes Are Primarily Responsible for Stable Liver Transduction In Vivo , 2001, Journal of Virology.

[8]  M. Kaleko,et al.  Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs. , 2001, Blood.

[9]  P. Hearing,et al.  Adeno-Associated Virus (AAV) Rep Protein Enhances the Generation of a Recombinant Mini-Adenovirus (Ad) Utilizing an Ad/AAV Hybrid Virus , 2000, Journal of Virology.

[10]  James M. Wilson,et al.  Humoral Immunity to Adeno-Associated Virus Type 2 Vectors following Administration to Murine and Nonhuman Primate Muscle , 2000, Journal of Virology.

[11]  A. Bruce,et al.  Sustained expression of human factor VIII in mice using a parvovirus-based vector. , 2000, Blood.

[12]  James M. Allen,et al.  Repeat Transduction in the Mouse Lung by Using Adeno-Associated Virus Vectors with Different Serotypes , 2000, Journal of Virology.

[13]  C. Balagué,et al.  Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector. , 2000, Blood.

[14]  M. Kay,et al.  Integrating Adenovirus–Adeno-Associated Virus Hybrid Vectors Devoid of All Viral Genes , 1999, Journal of Virology.

[15]  K. Propert,et al.  Immune responses to adenovirus and adeno-associated virus in humans , 1999, Gene Therapy.

[16]  R. Cortese,et al.  Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Jesty,et al.  Human factor VIII can be packaged and functionally expressed in an adeno‐associated virus background: applicability to haemophilia A gene therapy , 1999, British journal of haematology.

[18]  D. Maglott,et al.  The Human Proteinase-activated Receptor-3 (PAR-3) Gene , 1998, The Journal of Biological Chemistry.

[19]  B. Trapnell,et al.  Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy. , 1998, Blood.

[20]  K. High,et al.  Gene therapy for the hemophilias. , 1999, Advances in veterinary medicine.

[21]  A. Helenius,et al.  The role of the adenovirus protease on virus entry into cells. , 1996, The EMBO journal.

[22]  J. Ryan,et al.  Sequence requirements for binding of Rep68 to the adeno-associated virus terminal repeats , 1996, Journal of virology.

[23]  S. Ponnazhagan,et al.  Rescue and replication of adeno-associated virus type 2 as well as vector DNA sequences from recombinant plasmids containing deletions in the viral inverted terminal repeats: selective encapsidation of viral genomes in progeny virions , 1996, Journal of virology.

[24]  M. Kaleko,et al.  High-level tissue-specific expression of functional human factor VIII in mice. , 1996, Human gene therapy.

[25]  Lynne,et al.  Site-specific integration by adeno-associated virus. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[26]  C. Giraud,et al.  Biology of adeno-associated virus. , 1996, Current topics in microbiology and immunology.

[27]  S. Ponnazhagan,et al.  Rescue and replication signals of the adeno-associated virus 2 genome. , 1995, Journal of molecular biology.

[28]  S. Antonarakis,et al.  Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A , 1995, Nature Genetics.

[29]  N. Muzyczka,et al.  The AAV origin binding protein Rep68 is an ATP-dependent site-specific endonuclease with DNA helicase activity , 1990, Cell.

[30]  N. Muzyczka,et al.  In vitro excision of adeno-associated virus DNA from recombinant plasmids: isolation of an enzyme fraction from HeLa cells that cleaves DNA at poly(G) sequences , 1988, Molecular and cellular biology.

[31]  J Jesty,et al.  Parlin, a general microcomputer program for parallel-line analysis of bioassays. , 1986, American journal of clinical pathology.

[32]  B. Lyons,et al.  Hemophilia A. , 1969, Oral surgery, oral medicine, and oral pathology.

[33]  B. Hirt.  Selective extraction of polyoma DNA from infected mouse cell cultures. , 1967, Journal of molecular biology.